27677842|t|Synthesis, characterization and drug loading property of Monomethoxy-Poly(ethylene glycol)-Poly(ε-caprolactone)-Poly(D,L-lactide) (MPEG-PCLA) copolymers
27677842|a|Amphiphilic block copolymers have attracted a great deal of attention in drug delivery systems. In this work, a series of monomethoxy-poly (ethylene glycol)-poly (ε-caprolactone-co-D,L-lactide) (MPEG-PCLA) copolymers with variable composition of poly (ε-caprolactone) (PCL) and poly (D,L-lactide) (PDLLA) were prepared via ring-opening copolymerization of ε-CL and D,L-LA in the presence of MPEG and stannous octoate. The structure and molecular weight were characterized by nuclear magnetic resonance (NMR) and gel permeation chromatography (GPC). The crystallinity, hydrophilicity, thermal stability and hydrolytic degradation behavior were investigated in detail, respectively. The results showed that the prepared amphiphilic MPEG-PCLA copolymers have adjustable properties by altering the composition of PCLA, which make it convenient for clinical applications. Besides, the drug loading properties were also studied. Docetaxel (DTX) could be entrapped in MPEG-PCLA micelles with high loading capacity and encapsulation efficiency. And all lyophilized DTX -loaded MPEG-PCLA micelles except MPEG-PCL micelles were readily re-dissolved in normal saline at 25 °C. In addition, DTX -loaded MPEG-PCLA micelles showed a slightly enhanced antitumor activity compared with free DTX. Furthermore, DTX micelles exhibited a slower and sustained release behavior in vitro, and higher DTX concentration and longer retention time in vivo. The results suggested that the MPEG-PCLA copolymer with the adjustable ratio of PCL to PDLLA may be a promising drug delivery carrier for DTX.
27677842	0	9	Synthesis	T052	C1883254
27677842	11	27	characterization	T052	C1880022
27677842	32	36	drug	T121	C1254351
27677842	37	44	loading	T052	C1708715
27677842	45	53	property	T080	C0871161
27677842	57	152	Monomethoxy-Poly(ethylene glycol)-Poly(ε-caprolactone)-Poly(D,L-lactide) (MPEG-PCLA) copolymers	T104,T122	C0032521
27677842	153	181	Amphiphilic block copolymers	T104,T122	C0032521
27677842	226	247	drug delivery systems	T074	C0085104
27677842	275	369	monomethoxy-poly (ethylene glycol)-poly (ε-caprolactone-co-D,L-lactide) (MPEG-PCLA) copolymers	T104,T122	C0032521
27677842	384	395	composition	T070	C0243176
27677842	399	420	poly (ε-caprolactone)	T109	C0137734
27677842	422	425	PCL	T109	C0137734
27677842	431	449	poly (D,L-lactide)	T122	C0071444
27677842	451	456	PDLLA	T122	C0071444
27677842	476	505	ring-opening copolymerization	T044	C1880180
27677842	509	513	ε-CL	T109	C0908527
27677842	518	524	D,L-LA	T109	C0293984
27677842	544	548	MPEG	T109	C0066763
27677842	553	569	stannous octoate	T109	C0963887
27677842	575	584	structure	T082	C0678594
27677842	589	605	molecular weight	T081	C0026385
27677842	611	624	characterized	T052	C1880022
27677842	628	654	nuclear magnetic resonance	T070	C0028580
27677842	656	659	NMR	T070	C0028580
27677842	665	694	gel permeation chromatography	T059	C0008559
27677842	696	699	GPC	T059	C0008559
27677842	706	719	crystallinity	T104	C0444626
27677842	721	735	hydrophilicity	T080	C0475370
27677842	737	744	thermal	T070	C0018837
27677842	745	754	stability	T080	C0205360
27677842	759	769	hydrolytic	T070	C0020291
27677842	770	790	degradation behavior	T169	C0243125
27677842	871	903	amphiphilic MPEG-PCLA copolymers	T104,T122	C0032521
27677842	920	930	properties	T080	C0871161
27677842	947	958	composition	T070	C0243176
27677842	962	966	PCLA	T109	C1744269
27677842	997	1018	clinical applications	T201	C0683325
27677842	1033	1037	drug	T121	C1254351
27677842	1038	1045	loading	T052	C1708715
27677842	1046	1056	properties	T080	C0871161
27677842	1076	1085	Docetaxel	T109,T121	C0246415
27677842	1087	1090	DTX	T109,T121	C0246415
27677842	1114	1123	MPEG-PCLA	T104,T122	C0032521
27677842	1124	1132	micelles	T109	C0025938
27677842	1138	1142	high	T080	C0205250
27677842	1143	1150	loading	T052	C1708715
27677842	1151	1159	capacity	T081	C1516240
27677842	1164	1177	encapsulation	T067	C2348438
27677842	1178	1188	efficiency	T081	C0013682
27677842	1198	1209	lyophilized	T080	C0205556
27677842	1210	1213	DTX	T109,T121	C0246415
27677842	1222	1231	MPEG-PCLA	T104,T122	C0032521
27677842	1232	1240	micelles	T109	C0025938
27677842	1248	1256	MPEG-PCL	T104,T122	C0032521
27677842	1257	1265	micelles	T109	C0025938
27677842	1279	1291	re-dissolved	T169	C0205245
27677842	1295	1308	normal saline	T121,T197	C0445115
27677842	1332	1335	DTX	T109,T121	C0246415
27677842	1344	1353	MPEG-PCLA	T104,T122	C0032521
27677842	1354	1362	micelles	T109	C0025938
27677842	1381	1389	enhanced	T052	C2349975
27677842	1390	1399	antitumor	T080	C2986475
27677842	1400	1408	activity	T052	C0441655
27677842	1428	1431	DTX	T109,T121	C0246415
27677842	1446	1449	DTX	T109,T121	C0246415
27677842	1450	1458	micelles	T109	C0025938
27677842	1471	1477	slower	T080	C0439834
27677842	1482	1491	sustained	T169	C0443318
27677842	1492	1499	release	T169	C1283071
27677842	1500	1508	behavior	T080	C0871161
27677842	1509	1517	in vitro	T080	C1533691
27677842	1523	1529	higher	T080	C0205250
27677842	1530	1533	DTX	T109,T121	C0246415
27677842	1534	1547	concentration	T081	C1264643
27677842	1559	1573	retention time	T081	C0392762
27677842	1574	1581	in vivo	T082	C1515655
27677842	1614	1633	MPEG-PCLA copolymer	T104,T122	C0032521
27677842	1654	1659	ratio	T081	C0456603
27677842	1663	1666	PCL	T109	C0137734
27677842	1670	1675	PDLLA	T122	C0071444
27677842	1695	1716	drug delivery carrier	T122	C0013161
27677842	1721	1724	DTX	T109,T121	C0246415